<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342053</url>
  </required_header>
  <id_info>
    <org_study_id>BN40697</org_study_id>
    <nct_id>NCT03342053</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of
      RO7234292 administered intrathecally to adult patients with Huntington's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">October 8, 2019</completion_date>
  <primary_completion_date type="Actual">October 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events [safety and tolerability]</measure>
    <time_frame>Participants will be followed for the duration of the study; an expected 74 weeks</time_frame>
    <description>The number of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF Huntingtin Protein Concentration (fM)</measure>
    <time_frame>74 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Volume (mL)</measure>
    <time_frame>74 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Electroencephalography</measure>
    <time_frame>74 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Huntington's Disease Cognitive Assessment Battery Composite Score (unitless)</measure>
    <time_frame>74 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>RO7234292 Monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO7234292 is administered every 28 days intrathecally for 14 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7234292 Bimonthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7234292 (RG6042)</intervention_name>
    <description>Intrathecal injection</description>
    <arm_group_label>RO7234292 Bimonthly</arm_group_label>
    <arm_group_label>RO7234292 Monthly</arm_group_label>
    <other_name>Tominersen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have completed dosing in ISIS 443139-CS1

        Key Exclusion Criteria:

          -  Any new condition or worsening of existing condition that could make the patient
             unsuitable for participation or interfere with the patient participating in and/or
             completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of British Columbia; The Centre for Huntington Disease</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef and St. Elisabeth GmbH ; Klinikum Bochum, Zentralapotheke</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2FG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cambridge - John van Geest Centre for Brain Repair</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences</name>
      <address>
        <city>Cardiff</city>
        <zip>CF24 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leonard Wolfson Experimental Neurology Centre</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

